221 related articles for article (PubMed ID: 34090364)
1. Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
Dhaka B; Sabarinathan R
BMC Cancer; 2021 Jun; 21(1):669. PubMed ID: 34090364
[TBL] [Abstract][Full Text] [Related]
2. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
[TBL] [Abstract][Full Text] [Related]
5. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
Barta JA; Pauley K; Kossenkov AV; McMahon SB
Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
[TBL] [Abstract][Full Text] [Related]
6.
Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
[TBL] [Abstract][Full Text] [Related]
7. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
10. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
Yan W; Liu G; Scoumanne A; Chen X
Cancer Res; 2008 Aug; 68(16):6789-96. PubMed ID: 18701504
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide estrogen receptor β chromatin binding in human colon cancer cells reveals its tumor suppressor activity.
Indukuri R; Jafferali MH; Song D; Damdimopoulos A; Hases L; Zhao C; Archer A; Williams C
Int J Cancer; 2021 Aug; 149(3):692-706. PubMed ID: 33754337
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
14. Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells.
Wang X; Yan J; Shen B; Wei G
Front Cell Dev Biol; 2021; 9():708066. PubMed ID: 34395436
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 in colon cancer.
Nakayama M; Oshima M
J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
[TBL] [Abstract][Full Text] [Related]
16. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer.
Lu L; Huang W; Hu W; Jiang L; Li Y; Wu X; Yuan D; Li M
Biochem Biophys Res Commun; 2019 Apr; 511(4):772-779. PubMed ID: 30833076
[TBL] [Abstract][Full Text] [Related]
17. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic.
Kadosh E; Snir-Alkalay I; Venkatachalam A; May S; Lasry A; Elyada E; Zinger A; Shaham M; Vaalani G; Mernberger M; Stiewe T; Pikarsky E; Oren M; Ben-Neriah Y
Nature; 2020 Oct; 586(7827):133-138. PubMed ID: 32728212
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer.
Kelkar MG; Thakur B; Derle A; Chatterjee S; Ray P; De A
Breast Cancer Res Treat; 2017 Aug; 164(3):603-615. PubMed ID: 28528452
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.
Pfister NT; Fomin V; Regunath K; Zhou JY; Zhou W; Silwal-Pandit L; Freed-Pastor WA; Laptenko O; Neo SP; Bargonetti J; Hoque M; Tian B; Gunaratne J; Engebraaten O; Manley JL; Børresen-Dale AL; Neilsen PM; Prives C
Genes Dev; 2015 Jun; 29(12):1298-315. PubMed ID: 26080815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
